Xeris Lifts 2026 Revenue Forecast to $395 Million-$405 Million
Xeris Biopharma raised its 2026 revenue forecast to $395M-$405M, up from $385M-$390M. Q3 revenue hit $107.225M, with Recorlev up 93% and Gvoke down 14%. 2030 outlook increased to over $1B. Growth attributed to higher patient demand for Recorlev.
How this was made
The 30-second read
Why it matters
The guidance raise signals stronger demand and may trigger buying pressure, but investors should watch for execution risk.
Market read
Guidance upgrades are a key catalyst for small‑cap biotech stocks, potentially moving XERS higher in the short term.
What to watch
Potential regulatory or reimbursement risks for Recorlev and Gvoke could temper upside.
Background
Xeris Biopharma reported Q3 results, showing revenue growth and product performance, and used the occasion to raise its full‑year outlook.
Ticker impact
Xeris Biopharma raised its full-year 2026 revenue guidance to $395‑$405 million, up from $385‑$390 million.
likely upside as investors price in higher revenue outlook
The company reported a 37% YoY revenue increase and upgraded its 2030 outlook, indicating momentum across its product lines.
Market effects
Higher biotech revenue guidance may lift peer sentiment in the rare‑disease space.
U.S. biotech sector could see modest gains.
Limited to niche biotech investors.
Counterpoint
If the guidance upgrade is already priced in, the stock may face short‑term profit taking.
Key entities
- ExecutiveJohn Shannon
Chairman and CEO of Xeris Biopharma, quoted on the guidance increase.
